

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>4</sup> : C12N 15/00, 1/16, C12P 21/02</p>	<p>A1</p>	<p>(11) International Publication Number: WO 88/ 10308 (43) International Publication Date: 29 December 1988 (29.12.88)</p>
<p>(21) International Application Number: PCT/US88/02129 (22) International Filing Date: 23 June 1988 (23.06.88) (31) Priority Application Number: 066,078 (32) Priority Date: 24 June 1987 (24.06.87) (33) Priority Country: US  (71) Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US). (72) Inventors: FINK, Gerald, R. ; 40 Ashton Road, Brookline, MA 02146 (US). TRUEHEART, Joshua ; 182 Arguello Boulevard, San Francisco, CA 94118 (US). ELION, Elaine, A. ; 136 Hudson Street, Somerville, MA 02144 (US).</p>	<p>(74) Agents: GRANAHAAN, Patricia et al.; Hamilton, Brook, Smith &amp; Reynolds, Two Militia Drive, Lexington, MA 02173 (US).  (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: PHEROMONE-INDUCIBLE YEAST PROMOTER



(57) Abstract

A yeast promoter inducible by the appropriate pheromone and a method of expressing a gene of interest in substantial quantities by placing it under the control of the inducible promoter. DNA encoding a protein of interest is fused or linked to a pheromone-inducible yeast promoter, such as the *FUS1* or the *FUS2* promoter, and the fusion is inserted onto a high copy vector; the resulting product is introduced into wild type yeast cells. Stimulation of these yeast cells by the appropriate pheromone results in induction of transcription of the yeast promoter and expression of the protein of interest in substantial quantities.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

PHEROMONE - INDUCIBLE YEAST PROMOTERDescriptionBackground

05 It is possible, using recombinant DNA technology, to  
clone and express in bacteria and yeast a variety of  
genes which are not present in such organisms as they  
occur in nature. For example, procedures for cloning DNA  
segments in E. coli, by inserting the DNA into a plasmid  
or bacteriophage genome, are well established and  
10 frequently used to isolate prokaryotic and eukaryotic  
genes.

The yeast Saccharomyces cerevisiae (S. cerevisiae)  
is also used as a host for heterologous gene expression  
and protein secretion. Availability of techniques which  
15 make it possible to introduce exogenous DNA into yeast  
genomic DNA has made it possible to develop yeast strains  
which produce and secrete foreign proteins such as alpha  
interferon, epidermal growth factor, calf prochymosin and  
beta-endorphin. Heterologous eukaryotic genes can be  
20 expressed in S. cerevisiae if they are placed under the

-2-

control of a yeast gene promoter region. Heterologous protein yields will be determined, at least in part, by the promoter chosen. As an example, the promoter from the yeast gene for phosphoglycerate kinase (PGK) has been described as directing expression of heterologous genes with efficiency at least 500-fold greater than that evident when the TRP1 promoter is used. Mellor, J. *et al.*, Gene, 33:215-226 (1985). Hitzeman and co-workers describe work to increase expression of the gene encoding bovine growth hormone in yeast. The 5'-promoter region, translation signal and signal peptide sequences were replaced with yeast genomic DNA from similar regions. Hitzeman, R. A. *et al.*, Nature, 295:717-722 (1981).

The type of vector chosen (e.g., a high-copy-number 2 micron plasmid-based shuttle vector, rather than an unstable high-copy-number ARS-based plasmid or a low-copy-number stable ARS/CEN plasmid) also affects yields of heterologous proteins.

The availability of yeast promoters which are efficient in directing expression of a heterologous gene and whose activity can be regulated would be desirable.

#### Disclosure of the Invention

The present invention is based on the identification and isolation of two genes which are required for efficient cell fusion during yeast conjugation. Transcription of these two genes has been shown to be greatly induced by the presence of the appropriate mating pheromone. Expression of a gene of interest placed under the control of the promoter of either of these two genes has also been shown to be similarly induced by the presence of the appropriate mating pheromone. When the

-3-

promoter-gene of interest combination is present on a high-copy vector in yeast cells stimulated by the appropriate mating pheromone, expression of the fusion product is greatly increased.

05       According to the present invention, DNA encoding a protein of interest is placed under the control of a yeast (e.g., S. cerevisiae) promoter whose transcription is induced by the appropriate mating pheromone. Induction of the yeast promoter occurs as a result of  
10       stimulation by the appropriate mating pheromone.

          According to the present invention, DNA encoding the protein of interest (DNA of interest) is fused or linked to the pheromone-inducible yeast promoter, using known techniques; the promoter-DNA of interest fusion is  
15       inserted onto an appropriate vector; vectors containing the fusion are introduced into yeast cells (e.g., by transformation); and induction of transcription of the promoter is stimulated by the appropriate mating pheromone (i.e., alpha factor for a cells, a factor for  
20       alpha cells). Induction of the yeast promoter in this manner also results in expression of the DNA of interest which is under its control, resulting in production of the protein encoded by the DNA of interest. If the promoter-DNA of interest fusion is inserted onto a high  
25       copy vector (such as a high copy two micron vector), stimulation by the appropriate mating pheromone results in a significant increase in induction of the promoter-DNA of interest fusion and production of the encoded protein in substantial quantities. Thus, it is  
30       possible to clone DNA (i.e., an entire gene or a gene segment) encoding a protein or polypeptide in yeast, with expression of the DNA being controlled by the inducible

-4-

promoter; the promoter's activity is, in turn, determined by the presence or absence of stimulation by the appropriate mating pheromone.

In one embodiment, a DNA fragment from either the FUS1 gene or the FUS2 gene of S. cerevisiae, which includes the FUS1 promoter or the FUS2 promoter, respectively, is fused or linked, using techniques known to those skilled in the art, to DNA encoding a protein of interest. The DNA fragment of the FUS1 or FUS2 gene is a 5' segment or N terminal moiety. The yeast DNA fragment - DNA of interest fusion is inserted into a vector and the vector introduced into wild-type yeast cells. Upon stimulation of the yeast cells by the appropriate pheromone, induction of transcription of the yeast gene fragment (5' segment) occurs, the DNA of interest is expressed and a fusion protein which includes the FUS1 (or FUS2) -encoded protein sequence and the protein or polypeptide encoded by the DNA of interest is produced.

For example, DNA from the FUS1 gene which includes the FUS1 promoter and sequences encoding approximately the first 254 amino acids of FUS1 is fused to DNA encoding a protein or polypeptide of interest and the resulting combination inserted onto a high copy two micron vector (to produce a FUS1-DNA of interest plasmid). The resulting plasmid is introduced into wild-type a cells, which are incubated with alpha factor. Alpha factor induces a-type cells to respond; induction of the FUS1 promoter leads to induction of transcription of the DNA of interest to which it is fused. The result is expression of the FUS1-DNA of interest fusion protein (i.e., a fusion protein which is the FUS1-encoded

-5-

protein and the protein encoded by the DNA of interest) at substantial levels.

DNA encompassing the promoter from either the FUS1 gene or the FUS2 gene can be fused to DNA of interest, incorporated into an appropriate vector and introduced into yeast cells, which are incubated with the appropriate mating pheromone. Incubation in this manner causes induction of transcription of the fusion which includes the FUS1 promoter or the FUS2 promoter and DNA of interest and expression of the DNA, resulting in production of the encoded protein or polypeptide.

This approach can be used to produce proteins of interest in substantial amounts in yeast cells. The method of the present invention is particularly valuable because yeast cells containing the fusion can be grown up (cultured) passively and, after sufficient quantities of cells are produced, induced to express the fusion protein (containing the protein of interest) in substantial quantities. This is an important advantage because many foreign proteins are toxic to yeast cells.

#### Brief Description of the Drawings

Figure 1 is a schematic representation of chromosome III of the yeast Saccharomyces cerevisiae, on which the BIK-FUS1 region adjacent to HIS4 is shown.

Figure 2 shows results of Northern hybridizations of total RNA isolated from yeast strains treated with alpha-factor or solvent minus alpha-factor.

Figure 3 are immunofluorescence micrographs of alpha-factor-induced spheroplasts fixed in formaldehyde and incubated with anti-beta-galactosidase antibody and FITC-conjugated anti-mouse Ig.

-6-

Figure 4 presents the nucleotide sequence of the BIK1-FUS1 region. Position 1 corresponds to position -245 of the HIS4 gene.

05 Figure 5 presents the nucleotide sequence of the FUS2 gene and the deduced amino acid sequence. It includes approximately 500 nucleotides upstream and, thus, encompasses the hexameric repeats thought to be required for regulation.

#### Detailed Description of the Invention

10 The yeast S. cerevisiae can exist in a diploid or a haploid state; in the former, it has 17 pairs of chromosomes and, in the latter, a single set of chromosomes (one copy of each of the 17 chromosomes). Under favorable conditions, yeast cells exist in the  
15 diploid state and multiply rapidly. Multiplication occurs through mitosis, the process by which a diploid cell duplicates its chromosome pairs and divides into a mother cell and a bud, each of which has two copies of every chromosome.

20 When conditions are unfavorable, yeast cells sporulate; cells stop dividing and undergo meiosis, with the result that they duplicate their chromosome pairs and divide into four cells, each having a set of chromosomes. These haploid cells are of either the alpha type or the a  
25 type. They can reproduce by mitosis, but produce only haploids as a result. They can enter the diploid life cycle by conjugation, during which an alpha cell and an a cell fuse to form a diploid cell.

30 Conjugation in S. cerevisiae involves the fusion of haploid cells of opposite mating type, followed by the fusion of nuclei to form a diploid. The zygote formed by



-7-

this process buds off diploid cells capable of vegetative growth. Formation of the zygote requires the coordination of two processes--cell fusion and nuclear fusion. Both processes are initiated by mating pheromones: a cells produce a-factor, to which alpha cells specifically respond, and alpha cells produce alpha-factor, to which a cells specifically respond. Duntze, W.D. et al., European Journal of Biochemistry, 35:357-365 (1973); Wilkinson, L.E. and J.R. Pringle, Experimental Cell Research, 89:175-187 (1974).

Cells stimulated by the appropriate mating pheromone produce surface agglutinins (resulting in extensive clumping of conjugating cultures), arrest their cell-cycle at the G1 stage, and elongate to form a discernible tip (a process dubbed "shmooing"). When the appropriate partners have achieved contact, presumably at the shmoo tip, the cells rapidly fuse. Cell fusion requires the degradation and/or reorganization of the cell wall and the fusion of the two plasma membranes. The nuclei subsequently fuse within the dumbbell-shaped zygote formed and the resultant diploid nucleus begins a series of division cycles, each of which yields a new diploid nucleus that enters an emerging bud. Nuclear fusion is not a passive process; like cell fusion, it requires potentiation by the mating factors. Curran, B.P.G. and B.L.A. Carter, Current Genetics, 10:943-945 (1986); Rose, M.D., et al., Molecular and Cellular Biology, 6:3490-3497 (1986).

Two genes involved in the initial zygote formation (cell surface reorganization leading to cytoplasmic fusion) have been identified. They have been designated FUS1 and FUS2. Cloning of FUS1 and FUS2 revealed that

-8-

they share some functional homology. That is, FUS1 on a high copy plasmid can partially suppress a FUS2 mutant; the opposite is also true. FUS1 is essentially unexpressed in vegetative cells, but is strongly induced by incubation of haploid cells with the appropriate mating pheromone. When a cells are incubated with alpha factor, transcription of FUS1 and FUS2 is strongly induced. The same is true of FUS1 when alpha cells are induced by a factor. Mutations in these genes block the conjugation process at a point following cell contact, preventing cytoplasmic fusion and, as a result, nuclear fusion. Genes containing these mutations have been designated fus, for cell fusion defective.

The expression of these FUS genes has been shown to be activated by mating pheromones, an induction that leads to the appearance of the gene product at the tip of the shmoo. This localization suggests that the defect observed in matings between mutants is a direct result of the absence of the gene product, rather than a symptom of some general metabolic defect. Investigation of the FUS1 gene has shown that it is not expressed in vegetative haploid a and alpha cells and diploid a/alpha cells and achieves high levels only in the presence of mating pheromones, suggesting that it functions exclusively during the actual conjugation process.

Induction of the level of FUS1 mRNA was assessed to determine whether its expression is altered during conjugation. Assessment of FUS1 transcription is described in Example 1.

Similarly, when cells containing the FUS1 gene or a portion including the FUS1 promoter fused to DNA of interest are exposed to the appropriate mating pheromone

-9-

(alpha factor), transcription of the FUS1 promoter is greatly induced, and leads to induction of transcription of the DNA which is under the control of the FUS1 promoter. Pheromone induction has been demonstrated by  
05 expression of a fusion protein encoded by a FUS1-LACZ fusion which has two components: a FUS1 fragment including the FUS1 promoter region and sequences encoding approximately the first 254 amino acids of FUS1 and the  
10 gene encoding beta-galactosidase. Exposure of wild-type a cells containing the fusion on a high-copy 2 micron vector resulted in at least 1000-fold induction of beta-galactosidase. When single-copy derivatives of this fusion were used, an equivalent induction ratio was observed. Pheromone induction has also been demonstrated  
15 by expression of a fusion protein encoded by a FUS1-SUC2 fusion, which includes a FUS1 fragment and the gene encoding invertase which lacks the normal signal sequence for invertase.

As a result of the work described herein, two highly  
20 inducible yeast promoters have been identified and can be used for achieving substantial levels of expression for a DNA sequence or gene of interest in yeast. The DNA sequence or gene of interest can encode a polypeptide or protein of interest (i.e., one whose expression is  
25 desired). Proteins and polypeptides of interest include those not normally expressed in yeast cells (i.e., heterologous proteins), as well as proteins normally expressed in yeast cells but at lower levels than can be achieved through use of the method of the present  
30 invention. As used herein, the term protein is meant to include proteins and polypeptides.

-10-

Recombinant DNA techniques known to those in the art are used to obtain the necessary genetic material and to introduce it into yeast cells, which are subsequently cloned. Maniatis, T., et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982).

The DNA encoding the protein or polypeptide of interest can be isolated by obtaining mRNA of the desired gene or gene segment. For example, double-stranded DNA can be produced from the mRNA by conventional means. First, a complementary copy of the DNA is made from the mRNA, using conventional RNA technology; the RNA is subsequently removed by breaking the strands, using art-recognized methods. The cDNA is then made double-stranded; E. coli DNA polymerase I can be used for this step.

Synthetic linkers can be added to both ends of the double-stranded DNA (e.g., by using HindIII or EcoRI synthetic oligonucleotide linkers). cDNA having linkers at both ends is introduced into the unique site of a plasmid, which has been cut with the appropriate restriction enzyme. DNA having linkers at both ends can, alternatively, be introduced into a virus or cosmid. For example, pBR322, pM89 or lambdagtWES can be used for this purpose.

Transformation of bacteria with the ligation products will result in transformation of only a fraction of the cells. Of those cells which are transformed, only a portion will contain the recombinant plasmid. Isolation of bacteria containing the initial plasmid and the recombinant plasmid can be accomplished if the initial vector contains a selectable genetic marker, such

-11-

as drug resistance (e.g., antibiotic resistance). When grown on media on which only those cells containing the selectable marker can survive (e.g., on ampicillin-containing media in the case of an ampicillin resistance marker), bacteria containing the initial plasmid and the recombinant plasmid will be the only cells to survive. A further step will be necessary to isolate cells containing the recombinant plasmid (unless the DNA of interest confers a distinguishable phenotype on cells in which it occurs). This can be done, for example, by isolating and separating DNA from transformed cells and analyzing the DNA to identify cells containing the recombinant plasmids. This can be done, for example, by electrophoresis or sequence analysis.

After the recombinant plasmid is cloned, isolated and identified, bacterial cells in which it is included can be grown, resulting in increased numbers of the recombinant plasmid.

The recombinant DNA molecule can be introduced into yeast cells, using conventional procedures. Ito, H. et al., Journal of Bacteriology, 153:163-168 (1983). That cells contain the recombinant DNA molecule can be verified, both by genetic and hybridization techniques.

Host cells (e.g., S. cerevisiae) containing the recombinant DNA molecule are then cultured (in standard media and under standard conditions); once grown, yeast cells are stimulated by the appropriate mating pheromone. This results in induction of transcription of the yeast gene fragment and expression of the protein or polypeptide of interest in substantial quantities. The protein or polypeptide is produced as part of a fusion protein, which includes the FUS1 (or FUS2) -encoded

-12-

protein and the protein or polypeptide encoded by the DNA of interest. The protein or polypeptide is subsequently removed or released from the fusion protein; this can be done, for example, by including a cassette which encodes the invertase signal sequence. This results in secretion of the fusion protein, followed by removal of the signal sequence.

Vectors containing the pheromone-inducible yeast promoter and DNA of interest can be constructed. For example, a recombinant plasmid can be constructed in vitro, using known techniques. One example of such a plasmid includes: the FUS1 promoter, the initiation region of FUS1, and the gene of interest; optionally it can also contain the FUS1 signal peptide. Alternatively, a plasmid can include a 5' segment or an N terminal moiety of the FUS1 gene which also encompasses DNA encoding approximately the first 254 amino acids; a gene of interest; a selectable marker (e.g., ura3) in yeast; a 2 micron autonomously replicating sequence (ARS); a selectable marker (e.g., amp<sup>r</sup>) in bacteria and a replication origin for producing the plasmid in E. coli. An example of an appropriate plasmid into which the FUS1 DNA fragment can be inserted is YEp24.

In one embodiment of the method of the present invention for expressing proteins or polypeptides of interest in yeast, a DNA fragment from either the FUS1 gene or the FUS2 gene, which includes the FUS1 or the FUS2 promoter, respectively, is fused or linked to DNA or a gene encoding the polypeptide or protein (DNA of interest). The yeast DNA fragment can include nucleotide sequences in addition to those which make up the promoter sequence and, in one embodiment, also includes sequences

-13-

encoding approximately the first 254 amino acids of FUS1.  
The resulting promoter-DNA of interest fusion is  
incorporated into a plasmid, using conventional methods.  
The DNA which includes the yeast promoter and additional  
05 sequences and the DNA encoding the protein of interest  
can be produced through genetic engineering techniques  
(e.g., by cloning), can be synthesized mechanically or  
can be DNA isolated from yeast cells.

The FUS1 or FUS2 promoter will generally be fused or  
10 linked to the DNA or gene (i.e., with no intervening  
nucleotide sequences other than those which might be  
needed for joining the two components). However, the  
promoter and the DNA or gene can be separated by  
intervening sequences of any length, provided the DNA or  
15 gene is under the control of the promoter.

The FUS1-gene of interest fusion or the FUS2-gene of  
interest fusion is inserted on an appropriate (i.e., high  
copy) vector, which is introduced into yeast cells by  
techniques known to those in the art. The vector can  
20 also include a DNA sequence encoding a characteristic,  
such as ability or inability to metabolize a particular  
nutrient or drug resistance, which makes it possible to  
select cells into which the vector (and, thus, the  
promoter-DNA of interest fusion) has been introduced and  
25 in which the DNA it contains is being expressed. Cells  
containing the vector are selected (e.g., by culturing on  
media containing a substance or lacking a nutrient whose  
presence or absence determines cells' ability to survive)  
and, after the cells have grown, exposed to the  
30 appropriate mating pheromone.

Yeast cells containing the vector are exposed  
to/stimulated by the appropriate mating pheromone by the

-14-

addition of essentially pure (either synthetic or naturally occurring) mating pheromone to the culture medium in which the transformed cells are grown, by the addition of a crude preparation of the appropriate mating  
05 pheromone, or by culturing with yeast cells of the opposite mating type (i.e., culturing a cells containing the vector with alpha cells producing alpha factor).

In one embodiment of a recombinant plasmid which can be used in the method of the present invention, the  
10 following components are included: a) a fragment of a plasmid, such as pBR322, which includes the plasmid DNA replication origin, which makes it possible to propagate DNA in E. coli; b) DNA encoding a selectable genetic marker (e.g., a drug resistance gene, such as  $\text{amp}^r$ , which  
15 makes it possible to select bacteria (E. coli) containing the recombinant plasmid; c) a fragment of the yeast 2 micron autonomously replicating sequence (ARS); d) a DNA fragment encoding a selectable genetic marker (e.g., a drug resistance gene, such as  $\text{amp}^r$ ,  $\text{ura3}$ ), which makes it  
20 possible to select yeast containing the recombinant plasmid; e) a fragment of yeast genomic DNA which includes the FUS1 promoter and sequences encoding approximately the first 254 amino acids of FUS1 and makes induction as a result of stimulation by the appropriate  
25 mating factor possible; and f) DNA encoding a protein or polypeptide not normally produced in substantial quantities in yeast cells. The latter component is positioned in the construct so as to be under the optimal control of the FUS1 promoter; induction of the FUS1  
30 promoter leads to induction of transcription of the DNA of interest.



-15-

The promoters and the method of the present invention, can be used to express a protein of interest, such as tpa, kpa, calf renin and bovine growth hormone. The genes encoding each of these proteins can be the  
05 naturally-occurring gene or DNA encoding the protein can be synthesized. For example, as described above, the FUS1 promoter and the first 254 amino acids of FUS1 are fused, using known techniques, to the gene of interest. Maniatis, T. et al., Molecular Cloning: A Laboratory  
10 Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982). They are inserted onto a 2 micron high copy plasmid and introduced into a cells, again using known methods. a cells containing the plasmid and the FUS1 promoter-gene of interest fusion are stimulated  
15 by addition of growing alpha cells. In this way, the a cells are stimulated by the alpha factor and induction of the FUS1 promoter occurs and leads to induction of the DNA encoding the protein of interest.

In a method for obtaining expression of a protein or  
20 polypeptide of interest in yeast according to the present invention, a portion of either the FUS1 or the FUS2 gene which includes the respective promoter is fused to DNA encoding the protein or polypeptide. This is done in such a way that the DNA of interest is placed under the  
25 control of the FUS1 or FUS2 promoter; preferably, it is placed under the optimal control of the promoter. The fusion produced is introduced into cells, in which the genetic information is retained and passed on to subsequent generations. Construction of a yeast strain  
30 having these characteristics (a pheromone-inducible promoter linked to DNA encoding a protein or polypeptide of interest) is useful because such cells can be used

-16-

(e.g., commercially) to produce the encoded products. Large-scale yeast fermentation methods are well developed and S. cerevisiae has no disadvantageous characteristics (e.g., toxicity).

05        In a further embodiment of the present invention, DNA encoding protein or polypeptide of interest is introduced into yeast cells through the use of retroviral vectors containing the pheromone-inducible promoter, DNA of interest and other components necessary for expression  
10 of the encoded protein.

      The host cell, in which the pheromone-inducible promoter-DNA of interest fusion is expressed, will generally be the yeast strain S. cerevisiae. S. cerevisiae has distinct advantages, as explained  
15 previously. However, other yeast cells which can be transformed with the promoter-DNA of interest fusion can also be used.

      Cultivation of yeast can be carried out under well-standardized conditions; this is the case with yeast  
20 cells into which the promoter-DNA of interest fusion is introduced. For example, yeast cells can be grown on commonly used laboratory media, such as yeast nitrogen base (YNB, Difco). Stimulation of yeast cells to induce transcription of the promoter and DNA of interest can be  
25 carried out in this media, with the addition of mating factor, or of yeast cells of the opposite mating type (which will produce the pheromone necessary to stimulate induction). In one embodiment of the present invention, approximately 8 micrograms (5 micromolar) of mating  
30 factor is included per milliliter of culture media. If yeast cells containing the FUS1 DNA fragment - DNA of interest fusion are cultured with yeast cells of the

-17-

opposite mating type, an equal volume of each of the two types of yeasts is used. That is, cells of equal density and at the same stage of growth are cultured together; in this case, both types of cells are growing exponentially.

05       It is evident from the above description that the pheromone-inducible yeast promoter can be introduced into yeast cells, along with DNA which encodes one or more proteins of interest and transcription of which is under control of the promoter, and used to produce proteins  
10       having a wide variety of applications (e.g., as drugs, enzymes, constituents of foods and beverages).

      The present invention will now be illustrated with the following examples, which are not to be seen as limiting in any way.

15    Example 1   Induction of FUS1 and FUS2 by mating pheromones.

      Induction of the FUS1 and the FUS2 genes was assessed as follows: For induction by alpha-factor, cells were grown to Klett 40 in YPD or SC-ura (for  
20       selection of plasmids) which had been titrated to pH 4 with hydrochloric acid. Alpha-factor (Sigma Chemical Company) was added to a concentration of 5 micromolar (uM) (1:100 dilution of a 0.5 mM solution in methanol), or methanol was added to a concentration of 1%. Cells  
25       were grown for two additional hours at 30°C, at which time more than 90% of the alpha-factor treated population had arrested as shmoos or unbudded cells.

      For induction by a-factor, cells were pregrown in untitrated SC-ura to Klett 40-50, and then pelleted and  
30       resuspended in an equal volume of YPD media in which JY132 cells (MATa) or EEX8 cells (a/alpha) were growing

-18-

at a similar density, or in an equal volume of unconditioned YPD. The cells were then grown for two more hours at 30°C.

Northern analysis. Total RNA was isolated from cells treated for 2 hours with alpha-factor or from control cells using the method of Carlson and Botstein. Carlson, M. and D. Botstein, Cell, 28:145-154 (1982). The isolated total RNA was separated by electrophoresis through a 1.5% agarose denaturing gel, transferred to the nylon membrane GeneScreen Plus according to the manufacturer's instructions (New England Nuclear Research Products, Boston), and hybridized, either with labelled RNA obtained from in vitro SP6 transcription (Promega Biotec, Madison, WI) or with DNA labelled by nick translation. Maniatis, T. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982). To obtain a single-stranded probe specific for FUS1, a fragment internal to the gene was inserted into an SP6 vector in the proper orientation and transcribed in vitro in the presence of labelled nucleotide. The RNA probe extended from nucleotide 3635 to 4030 (see Figure 4) of the FUS1 gene. The DNA probe consisted of the BIK1-FUS1 HindIII fragment inserted into the URA3 vector YIp5. Figure 2 shows the resultant autoradiogram, as well as a duplicate filter probed with the 6 kb HindIII fragment containing the entire FUS1-BIK1 region inserted into the URA3 vector YIp5. The addition of the alpha-factor pheromone to a/a cells, but not to isogenic a/alpha cells, caused an induction of a 1.6 kb message not observed in cells that were not exposed to the pheromone. The Northern blot on the left in Figure 2

-19-

is a control showing that an approximately equivalent amount of RNA was loaded onto each lane. The FUS1 gene is a prototype for the FUS2 gene. The same procedure was followed using the FUS2 gene and similar results were obtained.

Beta-galactosidase assays. Cells were permeabilized by vigorous agitation in Z-buffer supplemented with 0.0075% SDS and 60 ul/ml chloroform, and the assays were performed essentially as described by Miller. Miller, J.H., Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1972). Units of beta-galactosidase activity are expressed by the formula  $(1000 \times \text{O.D.}_{420} \text{ of centrifuged reaction mixture}) / (\text{O.D.}_{600} \text{ of culture} \times \text{volume of culture} \times \text{minutes of assay})$ .

Example 2 Construction and expression of FUS1-heterologous DNA.

The pheromone effect described in Example 1 was analyzed further by the construction of a FUS1-LACZ fusion that had the promoter region of FUS1 and sequences which encode the first 254 amino acids of FUS1 fused to beta-galactosidase. Addition of alpha-factor to wild type a cells containing this fusion on a high copy micron vector led to at least a 1000-fold induction of beta-galactosidase, as shown in Table 1.

-20-

Table 1. Induction of FUS1-LACZ by mating pheromone.

	Uninduced	Induced*
JY132(pSB234) ( <u>MATa</u> )	0.5	740
JY133(pSB234) ( <u>MATalpha</u> )	4.7	650

05 pSB234 is a 2 micron-URA3-based plasmid which encodes the  
FUS1-LACZ gene product; the fusion contained the first  
254 amino acids of FUS1 fused to beta-galactosidase.  
Units of activity were determined as described in Example  
1. An equivalent induction ratio was also seen for  
10 single copy derivatives of this fusion.

Incubation of alpha cells containing the same  
FUS1-LACZ plasmid with wild type a cells (a source of  
a-factor) also caused substantial induction; the  
uninduced level in alpha cells appeared to be  
15 significantly higher than in a cells. The same procedure  
was followed using the FUS2 gene and similar results were  
obtained.

Localization of FUS1-LACZ. The cellular location of the  
FUS1 gene product was determined by immunofluorescence  
20 microscopy on pheromone-treated cells containing the LacZ  
fusion. Kilmartin, J.V. and A.E.M. Adams, Journal of  
Cell Biology, 98:922-933 (1984). A mouse monoclonal  
alpha-beta-galactosidase antibody (provided by T. Mason)  
was used as a probe. It was visualized using a  
25 FITC-conjugated goat anti-mouse antibody (Boehringer  
Mannheim Biochemicals, Indianapolis, IN). Figure 3 shows  
a series of micrographs from such cells, with a CYC1-LACZ

-21-

fusion in similarly treated cells acting as a control fusion that should be cytoplasmic. In a large fraction of the cells, the FUS1-LacZ protein appears to be located exclusively at the tip of the shmoo. The FUS2-LacZ protein was localized using similar techniques. It appears to be located within the schmoo, but not at the tip of the schmoo.

Example 3 Determination of the sequence of the FUS1-BIK1 region.

10       The 6 kb HindIII fragment containing FUS1 and BIK1 was inserted into the unique HindIII site of YCp50, in the orientation bla-BIK1-FUS1-tet. Farabaugh, P.J. and G. R. Fink, Nature, 286:352-356 (1980). The unique BamHI site of this plasmid was subsequently destroyed by  
15       filling in the ends with Klenow fragment and religation of the blunt ends, generating pJef423. All complementation analyses were performed using derivatives of this plasmid.

20       Linker insertion mutagenesis was performed by DNase I nicking, micrococcal nuclease digestion followed by digestion with S1 nuclease, and ligation of BamHI linkers, essentially as described by Shortle. Shortle, D., Gene, 22:181-189 (1983). The sequence of the BIK1-FUS1 region was obtained by inserting various  
25       restriction fragments, including those obtained from the BamHI insertions, into the M13 phage derivatives mp18 and mp19, and sequencing by the dideoxy chain termination method. Biggin, M.D. et al., Proceedings of the National Academy of Sciences, U.S.A., 80:3963-3965 (1983); Sanger,  
30       F. et al., Proceedings of the National Academy of Sciences, U.S.A., 74:5463-5467 (1977).

-22-

The precise structure of the cloned FUS1 gene was determined by dideoxy sequencing of a collection of M13 mp18 and M13 mp19 phage containing different segments of the entire region, including BIK1 sequences. The sequence is presented in Figure 4. Except for small stretches of the intervening open reading frame, sequencing was carried out on both strands of the DNA. The sequence differs at four positions between nucleotides 519 and 540 from that previously determined. Donahue, T.F. *et al.*, Gene, 18:47-59 (1982). In three of these positions, an extra T was determined to occur and at one position, a T rather than an A was found. The sequence of this region is: GTAGCTGTTTCATTCTCAGCGTC. The BIK1 coding region extends to within 14 bases of the first upstream repeat (TGACTC) of the HIS4 gene.

The FUS1 and FUS2 genes were isolated as described below. For FUS1, this was done as follows: A yeast strain (L1052) containing a large deletion ( $\Delta$ 453) extending from HIS4 to LEU2 was transformed with various derivatives of pJef423 harboring linker insertions. These transformants were assayed by the replica-plating test for their ability to mate successfully with a  $\Delta$ 453 tester lawn, L1546. Large linker-associated deletions (e.g. 550, 552; Figure 1) in the HindIII fragment completely abolished the ability of the plasmid to complement the  $\Delta$ 453 defect; however, less extensive linker-associated deletions (e.g. 514, 543) and "simple" linker insertions (less than 50 bp deleted; 518, 483) only partially compromised the complementing activity of the HindIII insert. From this mutational analysis, a portion of which is presented in Figure 1, a map was constructed which contains two distinct regions of



-23-

complementing activity; either region alone is able to restore only partial mating competence to the  $\Delta 453$  recipient.

05 With the exception of 565, 566, 514, and  $\Delta 136$ , all of the mutations shown in Figure 1 were integrated into the chromosome of wild type cells (JY132 and JY133). The linker insertions were moved to URA3 integrating vectors, and the resultant plasmids were directed to integrate at chromosome III by cutting at the unique KpnI site before  
10 transformation. Orr-Weaver, T. L. et al., Proceedings of the National Academy of Sciences, U.S.A., 78:6354-6358 (1981).

The recipient strains harbored the his4-34 mutation, which lies within the region of his4 that is duplicated  
15 upon integration of these plasmids. Therefore, His<sup>+</sup> recombinants were selected for, in order to obtain the appropriate "loop-out" excision event. Those His<sup>+</sup> derivatives which had simultaneously become Ura<sup>-</sup> harbored the appropriate linker insertion (or frameshifted  
20 restriction site) and no plasmid sequences. Complementation tests using these strains transformed with the original set of pJef423 derivatives confirmed the idea that two genes required for efficient mating (FUS1 and FUS2) reside on the HindIII fragment upstream  
25 from HIS4.

The fus2-1 mutation was uncovered in a cross between C52a and JY145 (fus1-483). Several tetrads from this cross produced one ascospore which, when mated to  $\Delta 453$  lawns, displayed a drastic defect as compared to the  
30 response with wild type lawns. (fus1 alone displays only a partial defect when mated to  $\Delta 453$ ). These segregants were outcrossed to wild type strains, and the segregation

-24-

of wild type (good mating with all lawns), partially defective (poor mating with mutant parent lawns, but partial mating with fus1 lawns), and completely defective (poor mating with fus1 lawns and with mutant parent lawns) phenotypes among the spore clones suggested the presence of two unlinked fus mutations in the mutant parent. Single fus mutants mate poorly with double mutants, but partially with single mutants, and conversely, double mutants mate poorly with single mutants and double mutants (but mate well with wild type). The mating type of mutants does not affect their phenotype as assayed by replica plating.

The fus1 mutation was identified in strains carrying a deletion extending from HIS4 to LEU2 (Figure 1). This large deletion, designated  $\Delta$  453, had no obvious effect on the vegetative growth of the cells, but subsequent genetic manipulations revealed that  $\Delta$  453 strains form diploids at greatly reduced rates with strains carrying the same deletion, but at relatively normal rates with wild type strains. A centromere plasmid bearing the 6 kb HindIII fragment beginning in HIS4 and extending towards LEU2, subcloned from a 15 kb HIS4 BamHI-EcoRI fragment (isolated by "eviction"), was found to restore normal mating to a  $\Delta$  453 strain (L1052), suggesting that this segment contains the mating functions missing from  $\Delta$  453. Donahue, T.F. et al., Cell, 32:89-98 (1983).

Extensive deletion analysis and random linker insertion mutagenesis (a subset of which is presented in Figure 1) reveal that the phenotype of  $\Delta$  453 results from deletion of two separate genes, both of which are located on the HindIII fragment. The genes were further defined by introducing the linker insertions into the chromosome

-25-

of wild type cells and analyzing the behavior of the resulting strains in crosses. The linker insertions fall into two groups based on complementation tests. Insertions in one of these groups leads to a block in cellular fusion in crosses between members of the same group. The gene defined by this complementation group is called fus1. Mutants in the second group mate normally with wild type and fus1 mutants; however, in crosses with members of the same complementation group, the cells fuse normally but their nuclei fail to fuse. The gene defined by this complementation group is called bik1 (bilateral karyogamy defect). These experiments showed that the mating defect of  $\Delta 453$  results from the deletion of two genes: BIK1 and FUS1, each of which has its own unique function (see Figure 1).

Isolation of FUS2 was carried out as follows: The fus2 mutation was uncovered in crosses of fus1 by strain C52a, obtained from C. Nombela. The phenotype of fus1 mutants is rather leaky; many pairs in a fus1 x fus1 cross fuse their nuclei despite the abnormal bridge between the pair. In crosses of JY146 (alpha fus1-483 ura3-52 leu2-3, 112) by C52a (a exb1-1) several ascospore segregants were obtained which displayed a much more severe fusion defect than that of the fus1 mutant. These segregants were shown by genetic analysis to be double mutants, fus1 fus2. The fus2 mutation was apparently present in C52a, although it is not linked to the exb1-1 mutation described by Santos et al. (as assayed by the methylumbelliferyl-beta-D-glucoside overlay technique). As shown by subsequent tests, fus2 has a phenotype similar to that of fus1.

-26-

To clone the FUS2 gene, the severe mating defect of a fus2 mutant when mated with a fus1 fus2 double mutant was used. A FUS<sup>+</sup> strain can readily mate with a fus double mutant in the replica plating assay and the fus2 defect is recessive; as a result, cloning by complementation is straightforward. A MATa fus2 strain (JY306) was used as a recipient in transformation with the Yep24 library of Carlson and Botstein. Carlson, M. and D. Botstein, Cell, 28:145-154 (1982). A clone (pSB257) was identified (out of about 2000 screened) which restored normal mating function to fus2 when mated to fus1 fus2 (JY217). Genetic analysis demonstrates that the 9 kb DNA segment isolated corresponds to FUS2: crosses between FUS<sup>+</sup> strains and a fus2 strain harboring a FUS2<sup>+</sup> -URA3<sup>+</sup> plasmid integrated at fus2 yielded 19 out of 21 tetrads which contain 4 FUS<sup>+</sup> spores. One-step gene disruption by the substitution of an internal 1.1 kb HindIII fragment with the URA3 gene resulted in a phenotype identical to that of fus2-1: a gross mating defect with fus1 fus2 strains, but only slightly reduced diploid formation with either fus2-1 or fus2::URA3 strains.

#### Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

-27-

CLAIMS

1. A DNA fragment comprising a yeast promoter linked to DNA encoding at least one polypeptide not normally expressed at substantial levels in yeast cells,  
05 transcription of the yeast promoter inducible by a yeast mating pheromone, for directing the expression of the polypeptide-encoding DNA in yeast cells.
2. A DNA fragment of Claim 1 wherein the yeast promoter is a FUS1 promoter or a FUS2 promoter.
- 10 3. A DNA fragment of Claim 2 additionally comprising a nucleotide sequence encoding the first 254 amino acids of the FUS1 gene.
4. A DNA fragment of Claim 2 additionally comprising a nucleotide sequence encoding the first 617 amino  
15 acids of the FUS2 gene.
5. A DNA fragment of Claim 1 wherein the yeast promoter has the sequence consisting essentially of nucleotides 2550 to 3224 of Figure 4.
6. A DNA fragment of Claim 1 wherein the yeast promoter  
20 has the sequence consisting essentially of nucleotides 1 to 402 of Figure 5.
7. A DNA fragment of Claim 3 having the sequence consisting essentially of nucleotides 2550 to 3987 of Figure 4.

-28-

8. A DNA fragment of Claim 4 having the sequence consisting essentially of nucleotides 1 to 2253 of Figure 5.
- 05 9. Isolated DNA having the sequence consisting essentially of nucleotides 2550 to 3224 of Figure 4.
- 10 10. Isolated DNA having the sequence consisting essentially of nucleotides 2550 to 3987 of Figure 4.
11. Isolated DNA having the sequence consisting essentially of nucleotides 1 to 402 of Figure 5.
- 10 12. Isolated DNA having the sequence consisting essentially of nucleotides 1 to 2253 of Figure 5.
- 15 13. A yeast promoter, inducible by the appropriate mating pheromone, linked to DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
14. A yeast promoter of Claim 13 which is selected from the group consisting of the FUS1 promoter inducible by alpha factor and the FUS2 promoter inducible by a factor.
- 20 15. A recombinant DNA sequence which is nucleotides 2550 to 3987 of Figure 4 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.

-29-

16. A recombinant DNA sequence which is nucleotides 1 to 2253 of Figure 5 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
- 05 17. A recombinant DNA sequence which is nucleotides 2550 to 3224 of Figure 4 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
- 10 18. A recombinant DNA sequence which is nucleotides 1 to 402 of Figure 5 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
19. The recombinant DNA sequence of Claim 15, wherein the polypeptide is beta-galactosidase.
- 15 20. The recombinant DNA sequence of Claim 16, wherein the polypeptide is beta-galactosidase.
21. The recombinant DNA sequence of Claim 17, wherein the polypeptide is beta-galactosidase.
22. The recombinant DNA sequence of Claim 18, wherein the polypeptide is beta-galactosidase.
- 20 23. A method of expressing a protein or a polypeptide in yeast cells, comprising the steps of:
  - a. introducing into yeast cells a recombinant vector which contains a DNA fusion, the DNA fusion comprising a pheromone-inducible yeast
- 25

-30-

- promoter and DNA encoding a protein or a polypeptide to be expressed; and
- b. stimulating yeast cells containing the recombinant vector with the appropriate mating pheromone.
- 05
24. A method of Claim 23 wherein the recombinant vector is a recombinant two micron yeast vector.
25. A method of Claim 24 wherein the yeast cells are wild type a yeast cells and the mating pheromone is alpha factor.
- 10
26. A method of Claim 24 wherein the yeast cells are wild type alpha yeast cells and the mating pheromone is a factor.
27. A protein or a polypeptide produced by the method of Claim 25, wherein the DNA fusion has the sequence consisting essentially of nucleotides 2550 to 3987 of Figure 4 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
- 15
28. A protein or a polypeptide produced by the method of Claim 26, wherein the DNA fusion has the sequence consisting essentially of nucleotides 2550 to 3987 of Figure 4 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
- 20
- 25



-31-

- 05 29. A protein or a polypeptide produced by the method of Claim 25, wherein the DNA fusion has the sequence consisting essentially of nucleotides 1 to 2253 of Figure 5 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
- 10 30. A protein or a polypeptide produced by the method of Claim 26, wherein the DNA fusion has the sequence consisting essentially of nucleotides 1 to 2253 of Figure 5 fused with X, wherein X is DNA encoding a protein or polypeptide not normally expressed at substantial levels in yeast cells.
- 15 31. A protein or polypeptide produced by the method of Claim 25, wherein the DNA fusion has the sequence consisting essentially of nucleotides 2550 to 3224 of Figure 4 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
- 20 32. A protein or polypeptide produced by the method of Claim 26, wherein the DNA fusion has the sequence consisting essentially of nucleotides 2550 to 3224 of Figure 4 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
- 25 33. A protein or a polypeptide produced by the method of Claim 25, wherein the DNA fusion has the sequence consisting essentially of nucleotides 1 to 402 of Figure 5 fused with X, wherein X is DNA encoding a

-32-

protein or a polypeptide not normally expressed at substantial levels in yeast cells.

- 05 34. A protein or a polypeptide produced by the method of Claim 26, wherein the DNA fusion has the sequence consisting essentially of nucleotides 1 to 402 of Figure 5 fused with X, wherein X is DNA encoding a protein or a polypeptide not normally expressed at substantial levels in yeast cells.
- 10 35. A recombinant yeast cell containing an expression vector, the expression vector comprising a yeast DNA fragment including a pheromone-inducible promoter fused to DNA encoding a protein or polypeptide of interest, said protein or polypeptide not normally produced in significant amounts in yeast cells.
- 15 36. A recombinant plasmid comprising:
- a. the FUSI promoter;
  - b. DNA encoding approximately the first 254 amino acids of the FUSI gene;
  - c. DNA encoding a protein or a polypeptide of interest, the DNA positioned so as to be under the control of the FUSI promoter;
  - d. DNA encoding a selectable marker in yeast;
  - e. a two micron autonomously replicating sequence;
  - f. DNA encoding a selectable marker in bacteria;
  - 20 and
  - g. a replication origin for producing the plasmid in bacteria.
  - 25

-33-

37. A recombinant plasmid comprising:
- a. the FUS2 promoter;
  - b. DNA encoding approximately the first 614 amino acids of the FUS2 gene;
  - 05 c. DNA encoding a protein or a polypeptide of interest, the DNA positioned so as to be under the control of the FUS2 promoter;
  - d. DNA encoding a selectable marker in yeast;
  - e. a two micron autonomously replicating sequence;
  - 10 f. DNA encoding a selectable marker in bacteria; and
  - g. a replication origin for producing the plasmid in bacteria.
38. Plasmid YEp24 having inserted therein the  
15 recombinant DNA sequence of Claim 15.
39. Plasmid YEp24 having inserted therein the recombinant DNA sequence of Claim 16.
40. Plasmid YEp24 having inserted therein the recombinant DNA sequence of Claim 17.
- 20 41. Plasmid YEp24 having inserted therein the recombinant DNA sequence of Claim 18.




Fig. 1

2/14





FIG.2

3/14

FIG.3



SUBSTITUTE SHEET

FIG. 4.

1 TATTAGAGTCAGTTCGACTGCCTAGAGAAGCTGCTGGTTGTTCAGGATTGTGATGGGGGCATTCCTGCTGTATTATGACCCATCGTATCGCAATGCTCACACCACCTGTGTCTTCTTCGCCGT 120  
ATAATCTCAGTCAAGCTGACGGATCTCTTGACGACCAACAGCTCTAACACTACCCCGTAAGACGACATAACTACTGGTAGCATAGCGTTACGAGTGTGGTGACACACAGAACGACGGCA  
EndPhePheGlnGlnAsnAspProAsnHisHisProCysGluAlaThrAsnHisGlyMetThrAspCysHisGluCysTrpGlnGlnIArgGlyAlaThr

121 GGIATCGACTGGTGGCAGGGGGTCGAAAAATGGCAACGATTCCACGGCTGTTGTGCTTGAGCCGTGTCCAAGCTGTTCGATTTTTTCATTAGCCCTCTCAAGATTTTTTCGTTAAGGAATGC 240  
CCATAGCTGACCACGCTCCCCCAGCTTTTAACCGTTGCTTAAGGTGCCGACAAACACGAACTCGGACAAAGTTGACAAACTAAAAAGTAAATCGGAGAAAGTTCAAAAAAGCAATTCCTACG  
ThrAspValProAlaProAspPheLeuProLeuSerGluValAlaThrGlnAlaGlnAlaGlnGluLeuGlnLysIleLysGluAsnAlaGluGluLeuLysLysThrLeuSerAla

241 CACCTCTCCGATAGGAAATCTTGTGGTTTTGTCAAAAAATAGTTCCTTCGTCACAAATTTTTGGTATTCTTTTACTGACGGAATCGTTATGCAATTTTCAATTTGTCGGGTTCCTTAGCCCACTT 360  
GTGAGAGAAGCTACTCCTTAGAACACCAACCAACAGTTTTTATCAAGGAACGAGTTTTTAAACCATTAAGAAATGACTCGCTTAGCAATACGTAAAAAGTTAACAAAGCCGCAAGAAATCGGGTGAA  
ValGluGluSerSerAspGlnProLysThrLeuPheLeuGluLysSerLeuAsnGlnTyrGluLysSerLeuSerAspAsnHisMetLysLeuGlnGluArgGluLysAlaTrpLys

361 TGTCTTGTAACTCAAAATTTGGTCTTCTATGTTGGGTAAATGTTTCCAGCTGTTTTTTCAGGAGTTCGACATCTTCGTTGGCACCAGTGGGTGATTATGAGAAAGATTTCTCTCTTCGTT 480  
ACAGAACACATTTAGTTTAACCCAGAACATACAAACGCATTAACAAAGGTCGACAAAAAAGTCCCTCAAGCTGTAGAAAGCAACCGGTGGTCAACCAACTAATACTCTTTCTAAACAGAGAGAACAA  
ThrLysHisLeuGluPheGlnAspGluIleAsnArgLeuGlnGluLeuGlnLysLysLeuLeuGluValAspGluAsnAlaGlyThrProGlnAsnHisSerLeuAsnArgGluGluLysn

481 TTCITTGATCTCTTCGTGTAGTTGGCTTACGACACCAAGTAGCTGTTCATTCACGCGTCAAAAACCTGCTTTTGTGCTGGCTGCGGTCCCAATTTGTTGCTTCGATG 600  
AAGAAACTAGAGAACGACATCAACCCGAATGCTGTGCTTCATCGACCAAGTAAGAGTCGCAGTTTTTGAGCAAAACAAACGGAACGACAGACGAGCTCGAGGTAAACAGGAACCTCTAC  
GluLysIleGluGluHisLeuGlnSerValValAlaLeuLeuGlnGlnLysGlnLysAlaAspPhePheGlnLysAlaGlnGlnIArgArgGluLeuGluLeuGlnGlnLysLeuHis

## 5/14

601 GTCTATCTCTTCTCTTCTCTGATTGGCTTCATACCTATCAAAAGTCGGTTCACCTCTTCGAGGACCATTCTTTGGTCATCGAGTAGCCTTTTGTAGTGTAGTGTCTTTG 720  
CAGATAGAGAAAGAGAGAAAGACATAACACCGAAGTATGGATAGTTTCAGCCAAACGTCGAAGCTCTGGTAAGAAACCCAGTAGCTCATCGGAAACATCACATCAACAAGGAAAC  
AspIleGluLysGluArgGluGlnIleThrAlaGluTyrArgAspPheThrProGlnValGluGluLeuValMetArgGlnAspAspleuLeuArgLysTyrHisLeuGlnLysArgGln  
721 TAGCTTTTCGATGGTCAATTGGGCTTCTCGTAATTCAAATGTAACTTCGCTGCTATTGAGGTCATTCATGTGGCCATTGTCCGGTTTCCAAATCGCTGGTGGTGTGTGATTAGCCTTTCT 840  
ATCGAAAGCTACCCAGTTAACCCGAAGAGCATTAAGTTAAACATTTGAAGCGACGATAACTCCAGTAAGTACACCGGTAAACAGGCCAAAGGTTAGCGACCACCACACACTAATCGGAAAGA  
LeuLysGluIleThrLeuGlnAlaGluArgLeuGluIleThrValGluSerSerAsnLeuAspAsnMetHisGlyAsnAspProLysIrrpAspSerThrThrAsnHisAsnAlaLysArg  
841 GTCGTGATGACAGGATAGAGTCGACCTCCATTCTCTCTGTTATCGTAACCAAAATTCCTTGCTGTGATGGTGATCCGATGCCCTCCTCGGTCCATCGACTGTTGATACCGCTGTGCCG 960  
CAGACTACTGTCTCTATCTCAGCTGGAGGTAAAGACAGAGACAAATAGCATTGTTTAAAGAACGACAACTACCACTAGGCTACGAGGACCAAGGTAGCTGACAACTAATGGCGACACGGC  
AspSerSerLeuIleSerAspValGluMetArgAspGluArgAsnAspTyrGlyPheGluGlnGlnHisAspSerAlaGluGlnAspMetSerGlnGlnAsnGlySerHisArg  
961 ACTGGTGATCCGGAACCTCTCATGGGTGTGGGGATTAGGATCAATCCATGGGAGAGAACTGGTGTAGTCAGCCTCACAATAGATCTGTTTTGGGTATGTATACCGGGTCCATTGCTGT 1080  
TGACCACTAGGCCTTTGAAGAGTACCCACACCCCTAAATCCTAGTAGTACCTCTCTTGACCAATCACTCGGAGTGTATCTAGACAAAACCCATAACTATCGCCCAAGGTAAACAGCA  
SerThrIleArgPheSerArgMetProThrProSerLysProAspAspMetProSerPheGlnAsnThrLeuArgValIleSerArgAsnLysProLleSerLeuProGluMetThrThr  
1081 TCTTCTCGAGGTTTGGCATATCGATGCCCTTCTCGATCAATGATGGGACTTTTGGCAACTGAATAAATAGTCCACITTTGAGGATACCTCCGTTTGAATAATACTTCTTCCCCATGAATGATCC 1200  
AGAAAGACTCCAAACGCTATAGCTACGGAAAGCTAGTTACTAGCGCTGAAAAACGTTGACTTATTTATCAGGTGAAACCTCTATGAGGCAAACTTTTATGAAGAAGGGGTACTTACTAGG  
ArgArgSerThrGlnSerIleSerAlaLysGluIleLeuSerAlaValLysGlnLeuGlnIlePheLeuGlySerGlnProTyrGluThrGlnPheTyrLysLysGlyMetPheSerGly



## FIG. 4 CONT.

```

1201 ATCGTCTTACCAATGTTGGCAAGTAAGTCTACACCAGCAAAACATTCCAGCTTTCGIGTCCACTGGACCCACGATTTTCAGTTGTCCGCGCCCAAAATTTGGGATTTGTATGAACATCC 1320
TAGCAAGAAATGGTTACAACCGTTCAATTCAGATGTGGTCGTTTGTAAAGTTCGAAAGCACAGGTGACCTGGGTGCATAAAGTCAACAGCGCGGGGGTTTAAACCCCTAAACATACATTTGTAGG
AspAsnLysGlyIleAsnAlaLeuLeuAspValGlyAlaPheMetGlyAlaLysThrAspValProGlyValTyrLysLeuGlnGlyArgGlyLeuAsnProIleGlnIlePheCysGly

1321 TATCTTTCTTTGATATCTATCCATGGTATTTCAAACGGCATACACAGCCAGCCACAGCTCAACGCCCTTTACCTTGTCTCTTGTATGCCCTGTCTCGTCCAAACGTTTGTGGTGTCTTGGCCA 1440
ATAGAAAGAAACTATAGATAGGTA
IleLysArgGlnTyrArgAspMet ← BIK 1

1441 ATTGCCCTTCTGAAAAATCTCACTGTCGCAACTCATTTAAAGATACCCAGCAAGCTACACGATAAAGAAAGGAGAAAGTTTCATTTAAAGAACGTTACATATAGCGATACAAACGTATAG 1560

1561 CAAAGATCTGAAATGGATACGGATAAGTTAATCTCAGAGGCTGAGTCTCATTTTCTCAAGGAAACCATGCAGAAAGCTGTTTCGGAAGTTGACATCCGCAAGCTCAGTCGAACCCCAATGAC 1680
MetAspThrAspLysLeuIleSerGluAlaGluSerHisPheSerGlnGlyAsnHisAlaGluAlaValAlaLysLeuThrSerAlaAlaGlnSerAsnProAsnAsp

1681 GAGCAAAATGTCAACTATTGAATCAATTAATTCAAAAAATCGCAGGATACGTCAATGGACAACCGTAGTGGTAGTGACGCCCTCGCAAGATCGTGTGCTGGTGGTTCATCTTTTATG 1800
GluGlnMetSerThrIleGluSerLeuIleGlnLysIleAlaGlyTyrValMetAspAsnArgSerGlyGlySerAspAlaSerGlnAspArgAlaAlaGlyGlyGlySerSerPheMet

1801 AACACTTTAATGCGCAGACTCTAAGGGTTCTTCCCAAACCGCAACTAGGAAACTAGCTTTGTTAGCCACAGTGCATGACACACTCATCAAAATAAAGGTTCCTTCTAACAGAGGGTTTGACGTA 1920
AsnThrLeuMetAlaAspSerLysGlySerSerGlnThrGlnLeuGlyLysLeuAlaLeuLeuAlaThrValMetThrHisSerSerAsnLysGlySerSerAsnArgGlyPheAspVal

1921 GGGACTGTCATGTCATTAAGTGGTTCTGGCGGCGGAGCCAAAGTATGGGTGCTTCCGGCCTGGCTGGCTTGGCTTCTCAATTTCTTAAAGTCAGGTAAACAATTCCTCAAGGTCAGGGA 2040
GlyThrValMetSerMetLeuSerMetLysGlyGlySerGlnSerMetGlyAlaSerGlyLeuAlaAlaLeuAlaSerGlnPhePheLysSerGlyAsnAsnSerGlnGlyGlnGly

```

7114

2041 CAAGGTC AAGGTC AAGGTC AAGGTC AAGGTC AAGGTC TCTTTT TACTGCTTTT TGGCGTCTT TAACTTCATCTTT CATGAATTC CAACACAATAAT CAGC AAGGTC AAAAT 2160  
GInGlyGInGlyGInGlyGInGlyGInGlyGInGlySerPheThrAlaLeuAlaSerLeuThrSerPheMetAsnSerAsnAsnAsnGInGInGlyGInAsn

2161 CAAGGTC CGGTCGTTCTCTCTTTGGACCACTGGCTTCTATGGCAAGCTCTTTTATGCATTCCTCAATAATAATCAGAACTCCAACAATAGTCAACAGGGCTATAACCAATCTCTATCAAAAC 2280  
GInSerSerGlyGlySerSerPheGlyAlaLeuAlaSerPheMetHisSerAsnAsnAsnGInAsnSerAsnAsnSerGInGInGlyTyrAsnGInSerTyrGInAsn

2281 GGTAACCAAAATAGTCAAGGTTACAATAATCAACAGTACCAAGGTGGCAACGGTGGTTACCAACAACAACAGGGACAACTCTGGTGGTCTTTTTCCTCATTTGGCGCTCCATGGCTCAATCT 2400  
GlyAsnGInAsnSerGInGlyTyrAsnAsnGInGInTyrGInGInGlyGlyAsnGlyGlyTyrGInGInGInGInGlyGInSerGlyGlyAlaPheSerSerLeuAlaSerMetAlaGInSer

2401 TACTTAGTGGTGGACAAACTCAATCCAACCAACAGCAATACAATCAAC AAGGCCAAACAAACAGCAGCAATACCAGCAAC AAGGCCAAAACACTATCAGCATCAACAACAGGGTCAGCAG 2520  
TyrLeuGlyGlyGInThrGInSerAsnGInGInGInTyrAsnGInGInGInGlyGInAsnGInGInGInTyrGInGInGInGlyGInAsnTyrGInHisGInGInGInGInGIn

2521 CAGCAACAAGGCCACTCAGTTCATCTCAGCTTTGGCTTCCATGGCAAGTTCCTACCTGGGCAATAACTCCAATTCAAATTCGAGTTATGGGGCCAGCAACAGGCTAATCAGTATGGTA 2640  
GInGInGInGlyHisSerValHisSerGInLeuTrpLeuProTrpGInValProThrTrpAlaLeThrProLleGInLleArgValMetGlyAlaSerAsnArgLeuMetSerMetVal

2641 GACCGCAACAGAAATGGTCAACAGCAATCCAATGAGTACGGGAAGACCGCAATACGGCGGGAACCAACAGCAACTCCAATGGACAGCAGCAATCCTTCAATTTTTCTGGCAACTTTTTCTCAACAGA 2760  
AspArgAsnArgMetValAsnSerAsnProMetSerThrGluAspArgAsnThrAlaGluThrArgThrProMetAspSerThrAsnProSerIlePheLeuAlaThrPheLeuAsnArg

2761 ACAATAACGGCAACCAACGACCGCTACTGAACGATGATTCAGTTCGCCCTCTAICCTTTGTTACGTTATTTGTTATATATATACTTTATTTTTTATTAATTTGGGCTGCAAGACAAT 2880  
ThrIleThrAlaThrArgThrAlaThrGluArgGln

2881 ITTGTGTGTCAGTGAATGCTTCAATCTCTTTTGGTTCCTATATTTACCATGTGGACCCCTTTCAAAACAGAGTTGTATCTCTGCAGGATGCCCTTTTTGACGTTATGAAATGGCAATAATGTC 2999

## FIG. 4 CONT.

3000 ACTGTCACTTTTCGCGTGTCTCATTTCGGTCCGATGATGAACAACAACATGAACGCTCTGTAATTTGAACAATAAGGTAAATTCICGGGATTGGTTTATTTAAATGACAAATGTAAGAG 3119  
 . . . . .  
 3120 TGGCTTTGTAAGGTAAGTGTGCTCTTAAATAATTTGGATACGACATCCTTTATCTTTTTCCTTTAAGAGCAGGATATAAGCCATCAAGTTTCTGAAATCAAAATGGTAGCAACAATA 3239  
 . . . . .  
 FUS 1 → MetValAlaThrIle \*  
 3240 ATGCAGACGACAACAACACTGTGCTGACGACAGTCGCCGCAATGTCTACTACCTTAGCATCAAAATTACATATCITTCGCAAGCTAGTTCCTCGACGAGGTGAACAACAGTAACGACAATAGCG 3359  
 6 MetGlnThrThrThrValLeuThrThrValAlaAlaMetSerThrThrLeuAlaSerAsnTyrIleSerSerGlnAlaSerSerThrThrValThrThrIleAla  
 \* \* \* \* \*  
 3360 ACATCAATACCGCTACACCGTCTAACTACTCTTTTCTAAITGTGGCGGCTCAGCCAAAATCATCTTCAGCAAGCACAAATTCGGCTTTCAATCGGACTTCCCATCGGAATATTCTGTTTC 3479  
 46 ThrSerIleArgSerThrProSerAsnLeuLeuPheSerAsnValAlaAlaGlnProLysSerSerSerAlaSerThrIleGlyLeuSerIleGlyLeuProIleGlyIlePheCysPhe  
 \* \* \* \* \*  
 3480 GGATTACTTATCCTTTTGTGTTATTTCTACCTTAAAGGAATTCGGTGTCCATTTCAAATCCACCCATGTCAGCTACGATTCGAAGGGAAGGAATATGTCCGCCACTAAATTGGTTTC 3599  
 86 GlyLeuLeuIleLeuLeuCysTyrPheIleLeuLysArgAsnSerValSerIleSerAsnProProMetSerAlaThrIleProArgGluGluGluTyrCysArgThrAsnTrpPhe  
 . . . . .  
 3600 TCACGGTTATTTGGCAGAGTAAGTGTGAGGATCAGAAATCATATTCGTGATATTGACAAGTATACGACACCCAGTCGGGTGATAACATGTCTTCAAAAAATACAGTAC 3719  
 126 SerArgLeuPheTrpGlnSerLysCysGluAspGlnAsnSerTyrSerAsnArgAspIleGluLysTyrAsnAspThrGlnTrpThrSerGlyAspAsnMetSerSerLysIleGlnTyr  
 . . . . .  
 3720 AAAATTTCCAAACCCATAATACCGCAGCATATACTGACACCTAAGAAACGGTGAAGAACCCATATGCTTGGTCTGGTAAAAACATTTTCGTAGACCCCAAGAGTGAACGAAATGGAGGAA 3839  
 166 LysIleSerLysProIleIleProGlnHisIleLeuThrProLysLysThrValLysAsnProTyrAlaTrpSerGlyLysAsnIleSerLeuAspProLysValAsnGluMetGluGlu

8/14

## FIG. 4 CONT.

3840 GAGAAAGTTGGATGCTTCCTGATTAACCCGCAATATGTCCATATTTGAATCCAGCATGCCCTCGTATATGATTACCTTCTCAAAAACGGTGTCTCTCAAGAAAACCTGCG 3959  
 206 GtLysValValAspAlaPheLeuTyrThrLysProProAsnIleValHisIleGluSerSerMetProSerTyrAsnAspLeuProSerGlnLysThrValSerSerLysLysThrAla  
 3960 TTAAAAACGAGTGAGAAATGGAGTTACGAATCTCCACTATCTCGATGGTTCITGAGGGGTCTACATACCTTTAAGGATTATGGCTTATCAAAGACCTCTTTAAAGACCCCACTGGGCT 4079  
 246 LeuLysThrSerGluLysTrpSerTyrGluSerProLeuSerArgTrpPheLeuArgGlySerThrTyrPheLysAspTyrGlyLeuSerLysThrSerLeuLysThrProThrGlyAla  
 4080 CCACAACCTGAAGCAAAATGAAATGCTCTCCCGGATAGTAAGGGTTACTTCAATGAGTCAGATATTAATGCCCTGACCAACGATCGCCCATCTTGGAGTATAATAACACGCCCTCTGGATGCA 4199  
 286 ProGlnLeuLysGlnMetLysMetLeuSerArgIleSerLysGlyTyrPheAsnGluSerAspIleHetProAspGluArgSerProIleLeuGluTyrAsnAsnThrProLeuAspAla  
 4200 AATGACAGTGTGAATACTTGGGTAATACCAAGCCAGATTCAAAAATCAGATCTTATCGCAACAATAACATCGATCTAATCAGCGCAAGACCCCATTCAGTGATATACGGTACTACTGCA 4319  
 326 AsnAspSerValAsnAsnLeuGlyAsnThrThrProAspSerGlnIleThrSerTyrArgAsnAsnAsnIleAspLeuIleThrAlaArgProHisSerValIleTyrGlyThrThrAla  
 4320 CAACAAACTTTGGAAACCAACTTCAATGATCATCATGACTGCAATAAAAGCAGCTGAGAAACACGAGTTGATAATACCCACCCCATCAAAACCCACTAAAGAAAAGGAAAAAGAACACAA 4439  
 366 GlnGlnThrLeuGluThrAsnPheAsnAspHisAspCysAsnLysSerThrGluLysHisGluLeuIleleProThrProSerLysProLeuLysLysArgLysLysArgArgGln  
 4440 AGTAAATGTATCAGCATTTACAAACATTTGTACAGTTCTAAACCATTTGCCGTTACTCCAAACTCCAAATATAATGGGAGGCTAGCGTCCAATTAGGGAGACACATATACAGTTATTTCAG 4559  
 406 SerLysMetTyrGlnHisLeuGlnHisLeuSerArgSerLysProLeuProLeuThrProAsnSerLysTyrAsnGlyGluAlaSerValGlnLeuGlyLysThrTyrThrValIleGln  
 4560 GATTACGAGCCTAGATTGACAGACGAAATAAGAAATCTCGCTGGGTGAAAAGTTAAAAATCTGGCCACATACCGATGGTGTCTGGTAGAAAAGTGTAAATACACAAAAGGGTTCT 4679  
 446 AspTyrGluProArgLeuThrAspGluIleArgIleSerLeuGlyGluLysValLysIleleuAlaThrHisThrAspGlyTrpCysLeuValGluLysCysAsnThrGlnLysGlySer  
 4680 ATTACCGTCAGTTGACGATAAAAGATACCTCAATGAAGATAGAGCATTTGCTCGTGGTCACTGTCTCCAAGAAATACGACTGATGAAAAATAATATTGACGTTCCGATTAAATCTATACC 4799  
 486 IleHisValSerValAspAspLysArgTyrLeuAsnGluAspArgGlyIleValProGlyAspCysLeuGlnGluIleAspEndEnd End End

FIGURE 5 10/14

1 GATCTTTTGAATTTTGCATTAAACAGTGAAGAAGGTAGTAGAGACCGTTTCAAAGTCATA 60  
 CTAGAAAACCTTAAACGTAATTTGTCCTTCTTCCATCATCTCTGGCAAAGTTTCAGTAT  
 10 30 50

61 ACAGAGTTTTTAGGTAGAGGTGCCATCAGTTATTCTGACATCACTATTTAATGATGGATC 120  
 TGTCTCAAAAATCCATCTCCACGGTAGTCAATAAGACTGTAGTGATAAATTACTACCTAG  
 70 90 110

121 ATAACGATCTATTGTGCCCCGCCGTCACAAATGCGCCCCGAACTTGTCGCGAAGTTAAT 180  
 TATTGCTAGATAACACGGGCGGCGCAGTGTTTACGCGGGGCTTGAACAGCGCTTCAATTA  
 130 150 170

181 CTGAAACATATATGTTACCTAGTGAACACGCGCATGTTGGAAGACAAAGGTGAAGACG 240  
 GACTTGTATATACAATGGATGACTTTGTCGCGTACAACCTTTTCTGTTTCCACTTCTGC  
 190 210 230

241 AAGTTGTATATTTAAGATAGACCCTTTATACATCCTTTTGAAAAATTATTAATGTGGCA 300  
 TTCAACATATAAATTCTATCTGGGAAATATGTAGGAAAACCTTTTTAATAATTACACCGT  
 250 270 290

301 ACCGTCCTTTATTTGACAAAGTATCTTTTTTCTTTGTGAAACCAATTTTAGGTTTTCTTG 360  
 TGGCAGAAAAATAAAGTGTTCATAGAAAAAGAAACACTTTGGTTAAATCCAAAAGAAC  
 310 330 350

361 TTATAGTAAGTTCTTAAGAAAAAGACAAGAAAACCCCTTGCGATGTTTAAGACTTCATAT 420  
 AATATCATTCAAGAATTCTTTTTCTGTTCTTTTGGGGAACGCTACAAATTCTGAAGTATA  
 370 390 410

421 AsnLeuTyrAspLeuAsnTyrProLysAsnAspSerLeuThrProIleArgAspTyrLys  
 AACTTGACGATTTGAACTATCCGAAAAATGATTCATTAACGCCAATAAGAGACTACAAA 480  
 TTGAACATGCTAACTTGATAGGCTTTTTACTAAGTAATTGCGGTATTCTCTGATGTTT  
 430 450 470

481 AsnAspTyrPheHisLysAsnAspAspLysLeuProGluIleValArgLysProThrArg  
 AATGACTATTTTCATAAAAATGATGACAAATTACCAGAAATTGTTAGAAAACCTACGAGA 540  
 TTACTGATAAAAAGTATTTTTACTACTGTTAATGGTCTTTAACAACTTTTGGATGCTCT  
 490 510 530

11/14  
FIGURE 5. (CONT'D)

LysLeuSerLysHisGluAsnLysLeuAsnAspLysLysPheThrAsnLysArgProAla  
 541 AAGTTATCGAAACATGAAAACAACTCAACGATAAAAAATTACGAATAAACGACCAGCA 600  
 TTCAATAGCTTTTGTACTTTTGTGAGTTGCTATTTTAAAGTGCTTATTTGCTGGTCGT  
 550 570 590

SerLeuAspLeuHisSerIleValGluSerLeuSerAsnLysLysIleTyrSerProIle  
 601 AGTCTGGACTTGCATTCTATAGTGGAGAGCCTGAGCAATAAAAAAATTTACTCTCCTATT 660  
 TCAGACCTGAACGTAAGATATCACCTCTCGGACTCGTTATTTTAAATGAGAGGATAA  
 610 630 650

AsnThrGluIlePheGlnAsnValValArgLeuAsnLeuSerProGlnIleProAsnSer  
 661 AACACAGAGATATTTCAAATGTCTGTGAGACTGAATTTGAGCCCTCAGATTCCCAATTCT 720  
 TTGTGTCTCTATAAAGTTTTACAGCACTCTGACTTAACTCGGGAGTCTAAGGGTTAAGA  
 670 690 710

ProHisGluGlyCysLysPheTyrLysIleValGlnGluPheTyrLeuSerGluValGlu  
 721 CCTCAGAGGGATGCAAATTTTATAAATCGTACAGGAGTTTTACCTCTCTGAAGTGGAA 780  
 GGAGTGCTCCCTACGTTTAAATATTTTAGCATGTCTCAAATGGAGAGACTTCACCTT  
 730 750 770

TyrTyrAsnAsnLeuLeuThrAlaAsnAsnValTyrArgLysAlaLeuAsnSerAspPro  
 781 TATTACAATAATTTGTTAACTCGCAAATAACGTATACAGAAAGGCATTGAATAGTGATCCA 840  
 ATAATGTTATTAAACAATTGGCGTTTATTGCATATGTCTTCCGTAAGTTATCACTAGGT  
 790 810 830

ArgPheLysAsnLysLeuValLysLeuAspSerSerAspGluLeuLeuLeuPheGlyAsn  
 841 AGATTCAAGAATAAACTTGTCAAGCTTGATTCAAGTGACGAGCTATTGCTTTTTGGGAAC 900  
 TCTAAGTTCTTATTTGAACAGTTGGAAGTTCACTGCTCGATAACGAAAAACCTTG  
 850 870 890

IleAspThrIleAlaSerIleSerLysIleLeuValThrAlaIleLysAspLeuArgLeu  
 901 ATTGACACTATTGCGTCAATCAGCAAAATACTGGTAACGGCAATAAAAGACCTACGGTTA 960  
 TAACTGTGATAACGCAGTTAGTCGTTTTATGACCATTGCCGTTATTTCTGGATGCCAAT  
 910 930 950

AlaLysGlnArgGlyLysMetLeuAspAlaAsnGluTrpGlnLysIleLeuThrLysAsn  
 961 GCCAAGCAACGTGGGAAATGTTGGATGCGAATGAATGGCAAAAGATATTGACCAAAAT 1020  
 CGGTTTCGTTGCACCCTTTTACAACCTACGCTTACTTACCGTTTTCTATAACTGTTTTTA  
 970 990 1010

SUBSTITUTE SHEET

FIGURE 5 (CONT'D)

12/14  
 GluValGlnGlnGlnLeuTyrSerThrPheAspIleSerGluAlaPheGluGlnHisLeu  
 1021 GAGGTACAACAGCAGCTATATTCAACTTTTGATATTTTCAGAGGCGTTTCGAGCAACATTTG 1080  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 CTCCATGTTGTCGTCGATATAAGTTGAAAACATAAAAGTCTCCGCAAGCTCGTTGTAAC  
 1030 1050 1070  
  
 LeuArgIleLysSerThrTyrThrSerTyrPheValSerHisGlnLysGlnMetGluLeu  
 1081 TTAAGAATCAAATCCACCTACACAAGCTATTTTGTAGCCACCAAAAACAAATGGAACATA 1140  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 AATTCCTTAGTTTAGGTGGATGTGTTTCGATAAAACAATCGGTGGTTTTTGTGTTTACCTTGAT  
 1090 1110 1130  
  
 PheThrThrLeuArgMetAsnLysAsnHisPhePheAsnLysTrpTyrGluTyrCysLeu  
 1141 TTTACTACATTAAGGATGAATAAGAATCATTTTTTTTAAACAAGTGGTATGAATATTGTTTA 1200  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 AAATGATGTAATTCCTACTTATTCTTAGTAAAAAATGTTTCACCATACTTATAACAAAT  
 1150 1170 1190  
  
 LysGluSerGlyCysIleLysLeuGluAspIleLeuLysSerProMetLysArgLeuThr  
 1201 AAAGAGAGTGGATGTATAAAGTTAGAGGACATATTGAAAAGCCCGATGAAAAGACTGACT 1260  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 TTTCTCTCACCTACATATTTCAATCTCCTGTATAACTTTTCGGGCTACTTTTCTGACTGA  
 1210 1230 1250  
  
 GlnTrpIleAspThrLeuGluThrLeuGluSerCysTyrGluAspIleLeuSerProGlu  
 1261 CAGTGGATTGATACTTTGGAAACTTTGGAAAGCTGTTACGAAGATATTCTTTTCGCCAGAA 1320  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 GTCACCTAAGTATGAAACCTTTGAAACCTTTTCGACAATGCTTCTATAAGAAAGCGGTCTT  
 1270 1290 1310  
  
 LeuGlyLeuLysLeuSerProThrArgArgLysTyrSerLeuPheSerAsnLysLeuGlu  
 1321 TTGGGCTTGAACTAAGCCCGACAAGAAGAAAATATTCTTTATTTTCCAATAAGTTAGAA 1380  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 AACCCGAACCTTTGATTCGGGCTGTTCTTTCTTTTATAAGAAATAAAAGGTTATTCAATCTT  
 1330 1350 1370  
  
 ThrGluValSerGluTyrLysSerAsnSerMetTyrAsnPheSerLeuThrProSerGlu  
 1381 ACCGAGGTCTCCGAGTATAAGAGTAATTCATGTATAATTTTCAGTTTAACCCCATCAGAG 1440  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 TGGCTCCAGAGGCTCATATTCTCATTAAGGTACATATTAAAGTCAAATTGGGGTAGTCTC  
 1390 1410 1430  
  
 IleIleGlnSerTyrAspGluAspGlnPheThrHisLeuLeuLysProProAspLysGln  
 1441 ATTATACAAAGTTATGATGAAGATCAGTTTACACACCTTTTAAAACCCCCAGACAAACAA 1500  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 TAATATGTTTTCAATACTACTTCTAGTCAAATGTGTGGAAAATTTGGGGGTCTGTTGTT  
 1450 1470 1490  
  
 AsnLysAsnIleCysAsnAlaSerArgGlnGluSerAsnLeuAspAsnSerArgValPro

FIGURE 5 (CONT'D)

13/14  
 1501 AATAAAAATATATGTAATGCATCTCGACAAGAGAGTAATTTGGATAATAGTAGAGTTCCT 1560  
 -----+-----+-----+-----+-----+  
 TTATTTTTTATATACATTACGTAGAGCTGTTCTCTCATTAAACCTATTATCATCTCAAGGA  
 1510 1530 1550  
  
 SerLeuLeuSerGlySerSerSerTyrTyrSerAspValSerGlyLeuGluIleValThr  
 1561 TCTCTTCTTTCTGGATCATCGAGTTACTACTCAGATGTATCAGGGCTAGAAATTGTCACT 1620  
 -----+-----+-----+-----+-----+  
 AGAGAAGAAAGACCTAGTAGCTCAATGATGAGTCTACATAGTCCCGATCTTTAACAGTGA  
 1570 1590 1610  
  
 AsnThrSerThrAlaSerAlaGluMetIleAsnLeuLysMetAspGluGluThrGluPhe  
 1621 AATACTTCAACTGCGCTCAGCTGAGATGATAAATCTAAAAATGGATGAAGAAACAGAATTT 1680  
 -----+-----+-----+-----+-----+  
 TTATGAAGTTGACGGAGTCGACTCTACTATTTAGATTTTTACCTACTTCTTTGTCTTAAA  
 1630 1650 1670  
  
 PheThrLeuAlaAspHisIleSerLysPheLysLysValMetLysGlyLeuLeuGluLeu  
 1681 TTTACATTGGCAGATCACATCAGTAAATTCAAGAAAGTAATGAAAGGTTTGTTAGAATTA 1740  
 -----+-----+-----+-----+-----+  
 AAATGTAACCGTCTAGTGTAGTCATTTAAGTTCTTTCATTACTTTCCAAACAATCTTAAT  
 1690 1710 1730  
  
 LysLysAsnLeuLeuLysAsnAspLeuSerGlyIleIleAspIleSerLeuArgArgIle  
 1741 AAAAAGAATTTATTGAAAAACGATCTGTCAGGCATTATTGATATCAGTTTAAGAAGAATA 1800  
 -----+-----+-----+-----+-----+  
 TTTTCTTAAATAACTTTTTGCTAGACAGTCCGTAATAACTATAGTCAAATCTTCTTAT  
 1750 1770 1790  
  
 AsnAlaTrpLysLysValIleGluCysGluArgProSerGlyAlaPhePheAlaHisAsp  
 1801 AATGCAATGGAAAAAGGTGATCGAGTGCAGAACGCCCTTCTGGTGCATTTTTTGCGCACGAT 1860  
 -----+-----+-----+-----+-----+  
 TTACGTACCTTTTTCCACTAGCTCACGCTTGCGGGAAGACCACGTAAAAAACGCGTGCTA  
 1810 1830 1850  
  
 AsnLeuIleSerThrMetCysSerSerTyrIleAspLysLeuHisGluGlnLysAsnGln  
 1861 AACTTAATATCGACCATGTGTTCTTCGTACATAGATAAACTGCATGAACAAAAAATCAA 1920  
 -----+-----+-----+-----+-----+  
 TTGAATTATAGCTGGTACACAAGAAGCATGTATCTATTTGACGTACTTGTTTTTTTAGTT  
 1870 1890 1910  
  
 ValThrIleLeuLysLeuThrGluLeuGluThrAspValMetAsnProLeuGluArgIle  
 1921 GTAACAATTTTGAAACTCACAGAGCTCGAAACAGATGTGATGAACCCACTTGAAAGAATC 1980  
 -----+-----+-----+-----+-----+  
 CATTGTTAAACTTTGAGTGTCTCGAGCTTGTCTACACTACTTGGGTGAACCTTCTTAG  
 1930 1950 1970  
  
 IleAlaHisCysThrThrValLysSerLysLeuLysAspLeuGlnAlaTyrMetLeuPhe  
 1981 ATAGCCCATGTACTACCGTTAAAGCAAACCTAAAGATTTGCAAGCTTACATGTTATTT 2040  
 -----+-----+-----+-----+-----+



FIGURE 5 (CONT'D)

14/14

TATCGGGTAACATGATGGCAATTTTCGTTTGATTTTCTAAACGTTTGAATGTACAATAAA  
 1990 2010 2030

LeuGlnGluLysLysAlaAsnValArgAspIleLysArgAspLeuLeuGlyMetHisPhe  
 TTACAAGAAAAAAGCAAATGTGCGAGATATTAAACGTGACTTGTTGGGAATGCATTTT  
 2041 2100  
 AATGTTCTTTTTCGTTTACACGCTCTATAATTTGCACTGAACAACCTTACGTAAAG  
 2050 2070 2090

GlnAsnLeuGlnAsnGlnMetLysArgGluLeuProValPheIleThrLeuIleProArg  
 CAAAACCTGCAAAACCAGATGAAAAGGGAATTACCGGTCTTTATTACTTTGATCCCACGA  
 2101 2160  
 GTTTTGGACGTTTTGGTCTACTTTTCCCTTAAATGGCCAGAAATAATGAACTAGGGTGCT  
 2110 2130 2150

TyrTyrArgMetTyrLeuValGluLeuTyrGlnSerLeuLeuLysIlePheGlyAsnHis  
 TACTATCGAATGTATCTTGTTGAACTATATCAAAGTCTTCTTAAATATTTGGAAATCAT  
 2161 2220  
 ATGATAGCTTACATAGAACAACCTTGATATAGTTTCAGAAGAATTTTATAAACCTTTAGTA  
 2170 2190 2210

CysTrpTrpLysLysIleProAlaLysArgSer  
 TGCTGGTGGAAAAAATACCTGCAAAAGATCTTGAAATATGTCTCTTAATGACTCTAT  
 2221 2280  
 ACACACCTTTTTTTATGGACGTTTTTCTAGAACTTTTATACAGAGAATTACTGAGATA  
 2230 2250 2270

AGCTACCGGCCAAATTAAAAATCTTGATATTTTGCACTGTTATTCTAAATCAGATATAT  
 2281 2340  
 TCGATGGCCGGTTTAATTTTGAAGTATAAAACGTCACAATAAGATTTAGTGCTATATA  
 2290 2310 2330

ATGACAAAACGCATGGTAAGAAAAGATTGGCCTTTCCCTGGAGACCCTAGTGGAAGCCGT  
 2341 2400  
 TACTGTTTTGCGTACCATTCTTTTCTAACCGGAAAGGGACCTCTGGGATCACCTTCGGCA  
 2350 2370 2390

GTTGTGAGAAAACCTTTTCGAACCTTAAACAAAAGAGTATATTTAGCTTATAGTTTTAGAA  
 2401 2460  
 CAACAGTCTTTTGAAAAGCTTGAAATTGTTTTCTCATATAAATCGAATATCAAAAATCTT  
 2410 2430 2450

TGTTTTGTTTTGTTTTTACTAAAGTAGTACT  
 2461 2492  
 ACAAACAAAACAAAATGATTTTCATCATGA  
 2470 2490

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US88/02129

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : C 12 N 15/00, C 12 N 1/16, C 12 P 21/02						
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; font-size: small;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 5px; text-align: center;">           Classification System         </div> </td> <td style="width: 70%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 5px; text-align: center;">           Classification Symbols         </div> </td> </tr> <tr> <td style="border: none; text-align: center; vertical-align: middle;">           IPC<sup>4</sup> </td> <td style="border: none; text-align: center; vertical-align: middle;">           C 12 N; C 12 P         </td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 5px;">         Documentation Searched other than Minimum Documentation          to the Extent that such Documents are Included in the Fields Searched <sup>8</sup> </div>			<div style="border: 1px solid black; padding: 5px; text-align: center;">           Classification System         </div>	<div style="border: 1px solid black; padding: 5px; text-align: center;">           Classification Symbols         </div>	IPC <sup>4</sup>	C 12 N; C 12 P
<div style="border: 1px solid black; padding: 5px; text-align: center;">           Classification System         </div>	<div style="border: 1px solid black; padding: 5px; text-align: center;">           Classification Symbols         </div>					
IPC <sup>4</sup>	C 12 N; C 12 P					
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> *						
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>				
Y	Molecular and Cellular Biology, volume 7, No. 2, February 1987, p 749-759, (SCOTT W. VAN ARSDELL et al), "The Yeast Repeated Element Sigma Contains a Hormone-Inducible Promoter".	1-4, 13-14, 23-26, 35, 36				
P, Y	Chemical Abstracts, Vol 107 (1987) abstract No 212743x, (Trueheart), Mol.Cell.Biol.1987, 7(7), 2316-28 (Eng). *Abstract*	1-41				
P, Y	Chemical Abstracts, Vol 107 (1987) abstract No 128287u, (McCaffrey) Mol.Cell.Biol. 1987, 7(8), 2680-90 (Eng). *Abstract*	1-41				
P, Y	Chemical Abstracts, Vol 108 (1988) abstract No 217221f, (Nonato, Roberto V.) Biochem.Biophys.Res.Comm. 1988, 152(1), 76-82 (Eng). *Abstract*	1-4, 13-14, 23-26, 35, 36				
Y	EP, A2, 0 183 350 (IMMUNEX CORPORATION) 4 June 1986 *Claim 7*	1-4, 13-14, 23-26, 35, 36				
.../...						
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>						
<b>IV. CERTIFICATION</b>						
Date of the Actual Completion of the International Search  <div style="text-align: center; font-weight: bold;">23th September 1988</div>	Date of Mailing of this International Search Report  <div style="text-align: center; font-weight: bold;">11 NOV 1988</div>					
International Searching Authority  <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">   <b>P.C.G. VAN DER PUTTEN</b> </div>					

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	Chemical Abstracts, Vol 103 (1985) abstract No 208060x, (Miyajima Atusushi) Gene 1985, 37(1-3), 155-61 (Eng). *Abstract*	1-41
A	EP, A2, 0 123 544 (GENENTECH. INC.) 31 October 1984 *The whole document*	1-41
A	Chemical Abstracts, Vol 104 (1986) abstract No 220092n, (Vlasuk George P) J. Biol.Chem. 1986, 261(11), 4789-96 (Eng). *Abstract*	1-41
A	Chemical Abstracts, Vol 104 (1986) abstract No 16037u, (Singh Arjun et al) Genet:New Front., Proc.Int.Congr., 15th 1983 (Pub.1984). 2, 33-9 (Eng). *Abstract*	1-41
A	US, A, 4 615 974 (KINGSMAN et al) 7 October 1986 *The whole document*	1-41

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

PCT/US88/02129

SA

23281

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office (EPO) file on 01/09/88  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0183350	04-06-86	JP-A- 61199787	04-09-86
EP-A- 0123544	31-10-84	JP-A- 60041487	05-03-85
US-A- 4615974	07-10-86	EP-A- 0073635	09-03-83
		JP-A- 58077896	11-05-83
		AU-A- 560472	09-04-87
		DE-A- 3278365	26-05-88

EPO FORM P007

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82